Bronckers IMGJ, et al. - This study resolved to determine the patterns of use and relative risks of systemic agents for moderate to severe psoriasis in children. It was reported that medication-related adverse events (AEs) occur less often with tumor necrosis factor inhibitors than with methotrexate. Folic acid administration 6 or 7 times per week yielded greater protection against methotrexate-induced gastrointestinal AEs than did weekly administration. A need arose for prospective registry in order to track the long-term risks of systemic agents for pediatric psoriasis.